From code to rejuvenation: The race against human aging

As the world confronts a rapidly aging population and a widening gap between life expectancy and healthy life expectancy, scientists are increasingly turning to AI and cellular reprogramming in the search for a different way to grow old.

An unhealthy aging crisis

At the Sept. 18 “Code to Cure: The Rise of AI-Driven Healthcare Against Ageing” forum held in Nangang, Taipei, Wen Ming-hsuan (溫明璇), co-founder and chief executive officer of Nuwa Reprogramming, framed longevity not simply as a quest to live longer, but as a race to preserve health for longer.

Human life expectancy has risen substantially, yet longer lives do not necessarily translate into longer periods of good health.

The World Health Organization (WHO) stated that in 2020, people aged 60 and older outnumbered children under five for the first time, while projections indicate that 80% of the world’s older population will live in low- and middle-income countries by 2050.

Wen said at the forum that the demographic shift creates an increasingly consequential medical and social challenge: reducing the years people spend living with age-related disease and functional decline.

Reprogramming the biology of age

Wen’s proposed technological answer begins at the cellular level.

A Cambridge-trained developmental biologist, Wen studied under Nobel laureate John Gurdon, whose research helped establish that mature cells can be reprogrammed into states with greater developmental potential.

Gurdon’s pioneering work on nuclear reprogramming, followed by Shinya Yamanaka’s discovery of induced pluripotent stem cells, transformed the understanding of cellular differentiation and opened new avenues for studying disease and developing therapies.

At the forum, Wen explained nuclear reprogramming through the progression from an oocyte to a zygote, embryo and eventually a human being — a biological continuum in which developmental potential moves from totipotency to pluripotency and then multipotency.

She said that her research has focused on an epigenetic approach to cellular reprogramming that seeks to restore younger patterns of gene expression without inserting foreign genes.

Rather than returning mature cells to a fully embryonic or pluripotent state, Wen said the approach aims to rejuvenate cells while preserving their identity and function.

She said that her company is seeking to translate the technology into applications in regenerative and anti-aging medicine.

The prospect of Longevity Escape Velocity

The more audacious question is whether medicine could eventually advance quickly enough to offset the biological passage of time.

Wen discussed “Longevity Escape Velocity (LEV)” — a hypothetical point at which scientific and medical advances would add more than one year to a person's remaining life expectancy for every year that passes.

The concept remains speculative, but it has attracted predictions from prominent figures in longevity research, gerontology, and futurism.

Wen told TCN that Harvard geneticist George Church has suggested that 2050 could be a possible milestone, while American computer scientist and futurist Ray Kurzweil has projected a window of roughly 2029 to 2035.

Wen outlined her own prospective technological timeline: widespread adoption of epigenetic clocks and first-generation senolytics between 2026 and 2030; partial cellular reprogramming moving from animal models toward human therapies during the 2030s; and the integration of therapeutic nanomedicine with whole-organ 3D bioprinting between 2040 and 2050.

From AI to the clinic

Wen presented LEV as a hypothetical future milestone rather than an established medical endpoint. She projected a more comprehensive form of LEV beyond 2050.

She added that AI may accelerate the research process itself. She said Taiwan, particularly Nangang in Taipei, has become a hub driving the integration of biotechnology and AI.

The forum’s broader agenda placed these developments within a wider AI-driven healthcare landscape, covering cellular reprogramming, epigenetic rejuvenation, AI agents and biomedical high-performance computing, as well as commercialization and global market development.

Yet the distance between a prospective technological roadmap and clinical reality remains substantial.

The central scientific question is not simply whether aging can be delayed, but whether interventions that alter cellular aging can eventually be translated into therapies that are demonstrably safe and effective on humans.